Abstract

Antiplatelet drugs are essential in the prevention and treatment of cardiovascular diseases, necessitating a thorough understanding of platelet biology and drug mechanisms. This abstract explores the indispensable role of clinical pharmacology in the development of antiplatelet therapies. Through elucidating platelet biology, conducting pharmacokinetic and pharmacodynamic studies, and orchestrating clinical trials, clinical pharmacologists guide the optimization of antiplatelet agents. Moreover, personalized medicine approaches, informed by pharmacogenomics, enhance treatment efficacy and safety. As novel therapeutic strategies emerge, clinical pharmacology remains pivotal in advancing antiplatelet drug development, ultimately improving outcomes for patients with cardiovascular disorders.